<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Influenza antiviral drugs currently available and under clinical trial [
   <xref ref-type="bibr" rid="CR98">98</xref>, 
   <xref ref-type="bibr" rid="CR99">99</xref>]
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Drug</th>
    <th align="left">Generic name</th>
    <th align="left">Availability for use</th>
    <th align="left">Effective against</th>
    <th align="left">Specific Target</th>
    <th align="left">Status</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Oseltamivir</td>
    <td align="left">Tamiflu®</td>
    <td align="left">Oral</td>
    <td align="left">IAV and IBV</td>
    <td align="left" rowspan="3">Blocks NA protein and inhibit the release of virions after budding from the host cell</td>
    <td align="left" rowspan="3">Approved</td>
   </tr>
   <tr>
    <td align="left">Zanamivir</td>
    <td align="left">Relenza®</td>
    <td align="left">Inhalation</td>
    <td align="left">IAV and IBV</td>
   </tr>
   <tr>
    <td align="left">Peramivir</td>
    <td align="left">Rapivab®</td>
    <td align="left">Intravenous</td>
    <td align="left">IAV and IBV</td>
   </tr>
   <tr>
    <td align="left">Amantadine</td>
    <td align="left">Symmetrel</td>
    <td align="left" rowspan="2">Oral</td>
    <td align="left" rowspan="2">IAV</td>
    <td align="left" rowspan="2">Inhibits viral replication by blocking M2 membrane protein</td>
    <td align="left" rowspan="2">Approved but currently not in use due to high resistance to IAV</td>
   </tr>
   <tr>
    <td align="left">Remantadine</td>
    <td align="left">Flumadine</td>
   </tr>
   <tr>
    <td align="left">Baloxavir marboxil</td>
    <td align="left">Xofluza®</td>
    <td align="left">Oral</td>
    <td align="left">IAV and IBV</td>
    <td align="left">Inhibit the cap-dependent endonuclease protein</td>
    <td align="left">Approved</td>
   </tr>
   <tr>
    <td align="left">Nitazoxanide</td>
    <td align="left">Nizonide</td>
    <td align="left">Oral</td>
    <td align="left">IAV (H1, H3, H5, H7) and IBV</td>
    <td align="left">Inhibits replication of virus by vitiate the trafficking of the HA protein from the endoplasmic reticulum to the Golgi complex</td>
    <td align="left">Under clinical trial phase III</td>
   </tr>
   <tr>
    <td align="left">DAS181</td>
    <td align="left">Fludase®</td>
    <td align="left">Oral/inhalation</td>
    <td align="left">(H1N1)pdm09, H3N2, H7N9, H5N1 and IBV</td>
    <td align="left">Remove silaic acid receptor from host and block the binding and entry of virus to the host cell</td>
    <td align="left">Phase I,II</td>
   </tr>
   <tr>
    <td align="left">T705</td>
    <td align="left">favipiravir</td>
    <td align="left">Oral</td>
    <td align="left">IAV, IBV and ICV</td>
    <td align="left">Inhibitor of RNA dependent RNA polymerase</td>
    <td align="left">Phase II, III</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
